Addex Therapeutics Ltd (NASDAQ:ADXN) Short Interest Update

Addex Therapeutics Ltd (NASDAQ:ADXN) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 4,700 shares, a decline of 27.7% from the May 31st total of 6,500 shares. Based on an average daily volume of 18,600 shares, the short-interest ratio is presently 0.3 days. Currently, 0.6% of the company’s shares are short sold.

Addex Therapeutics Price Performance

Addex Therapeutics stock opened at $8.22 on Monday. The firm has a market capitalization of $8.71 million, a P/E ratio of -0.48 and a beta of 1.78. Addex Therapeutics has a 1-year low of $5.00 and a 1-year high of $27.90. The company’s 50-day moving average is $9.43 and its 200 day moving average is $10.51.

Addex Therapeutics (NASDAQ:ADXN) last issued its quarterly earnings results on Thursday, June 6th. The company reported ($1.37) earnings per share (EPS) for the quarter. The business had revenue of $0.27 million for the quarter. Addex Therapeutics had a negative return on equity of 364.24% and a negative net margin of 818.50%. Research analysts anticipate that Addex Therapeutics will post -11.8 earnings per share for the current fiscal year.

Institutional Trading of Addex Therapeutics

A hedge fund recently raised its stake in Addex Therapeutics stock. Armistice Capital LLC raised its stake in Addex Therapeutics Ltd (NASDAQ:ADXN) by 103.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 537,000 shares of the company’s stock after buying an additional 273,000 shares during the period. Armistice Capital LLC owned about 65.33% of Addex Therapeutics worth $206,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 16.14% of the stock is currently owned by institutional investors.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.